Our study demonstrated that the pre-treatment sMICA and TGF-β1 plasma levels were markedly elevated in HNSCC patients when compared to healthy controls, and patients with persistently elevated sMICA and TGF-β1 levels after treatment had a higher tumor progression rate. This evidence concerns the gene TGFB1 and neoplasm.